Literature DB >> 22512997

Socioeconomic disparities in lung cancer treatment and outcomes persist within a single academic medical center.

Jeffrey T Yorio1, Jingsheng Yan, Yang Xie, David E Gerber.   

Abstract

BACKGROUND: Socioeconomic disparities in treatment and outcomes of non-small-cell lung cancer (NSCLC) are well established. To explore whether these differences are secondary to individual or institutional characteristics, we examined treatment selection and outcome in a diverse population treated at a single medical center. PATIENTS AND METHODS: We performed a retrospective analysis of consecutive patients diagnosed with NSCLC stages I-III from 2000 to 2005 at the University of Texas Southwestern Medical Center. Treatment selection was dichotomized as 'standard' (surgery for stage I-II; surgery and/or radiation therapy for stage III) or 'other.' Associations between patient characteristics (including socioeconomic status) and treatment selection were examined using logistic regression; associations between characteristics and overall survival were examined using Cox regression models and Kaplan-Meier survival analysis.
RESULTS: A total of 450 patients were included. Twenty-eight percent of patients had private insurance, 43% had Medicare, and 29% had an indigent care plan. The likelihood of receiving 'standard' therapy was significantly associated with insurance type (indigent plan versus private insurance odds ratio [OR] 0.13, 95% confidence interval [CI] 0.04, 0.43 for stage I-II; OR 0.38, 95% CI 0.14, 1.00 for stage III). For patients with stage I-II NSCLC, survival was associated with age, sex, insurance type (indigent plan versus private insurance hazard ratio for death 1.98; 95% CI 1.16, 3.37), stage, and treatment selection. In stage III NSCLC, survival was associated with treatment selection.
CONCLUSION: Within a single academic medical center, socioeconomically disadvantaged patients with stage I-III NSCLC are less likely to receive 'standard' therapy. Socioeconomically disadvantaged patients with stage I-II NSCLC have inferior survival independent of therapy.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22512997      PMCID: PMC3436959          DOI: 10.1016/j.cllc.2012.03.002

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  35 in total

1.  Class - the ignored determinant of the nation's health.

Authors:  Stephen L Isaacs; Steven A Schroeder
Journal:  N Engl J Med       Date:  2004-09-09       Impact factor: 91.245

2.  Measuring race and ethnicity: why and how?

Authors:  Margaret A Winker
Journal:  JAMA       Date:  2004-10-06       Impact factor: 56.272

3.  Disparities between blacks and whites in tobacco and lung cancer treatment.

Authors:  Elyse R Park; Sandra J Japuntich; Lara Traeger; Sheila Cannon; Hannah Pajolek
Journal:  Oncologist       Date:  2011-09-29

4.  Disparities in cancer diagnosis and survival.

Authors:  C J Bradley; C W Given; C Roberts
Journal:  Cancer       Date:  2001-01-01       Impact factor: 6.860

5.  Racial/ethnic disparities in preschool immunizations: United States, 1996-2001.

Authors:  Susan Y Chu; Lawrence E Barker; Philip J Smith
Journal:  Am J Public Health       Date:  2004-06       Impact factor: 9.308

6.  Lung cancer in women compared with men: stage, treatment, and survival.

Authors:  D Ouellette; G Desbiens; C Emond; G Beauchamp
Journal:  Ann Thorac Surg       Date:  1998-10       Impact factor: 4.330

7.  Epidemiology of do-not-resuscitate orders. Disparity by age, diagnosis, gender, race, and functional impairment.

Authors:  N S Wenger; M L Pearson; K A Desmond; E R Harrison; L V Rubenstein; W H Rogers; K L Kahn
Journal:  Arch Intern Med       Date:  1995-10-23

Review 8.  Cancer disparities by race/ethnicity and socioeconomic status.

Authors:  Elizabeth Ward; Ahmedin Jemal; Vilma Cokkinides; Gopal K Singh; Cheryll Cardinez; Asma Ghafoor; Michael Thun
Journal:  CA Cancer J Clin       Date:  2004 Mar-Apr       Impact factor: 508.702

9.  Social and economic factors in the choice of lung cancer treatment. A population-based study in two rural states.

Authors:  E R Greenberg; C G Chute; T Stukel; J A Baron; D H Freeman; J Yates; R Korson
Journal:  N Engl J Med       Date:  1988-03-10       Impact factor: 91.245

10.  Racial differences pertaining to a belief about lung cancer surgery: results of a multicenter survey.

Authors:  Mitchell L Margolis; Jason D Christie; Gerard A Silvestri; Larry Kaiser; Silverio Santiago; John Hansen-Flaschen
Journal:  Ann Intern Med       Date:  2003-10-07       Impact factor: 25.391

View more
  22 in total

Review 1.  Elimination of socioeconomic and racial disparities related to lung cancer: closing the gap at a high volume community cancer center.

Authors:  Michael Z Caposole; Kaylee Miller; Jehovah-Nissi Kim; Nancy A Steward; Thomas L Bauer
Journal:  Surg Oncol       Date:  2014-02-20       Impact factor: 3.279

2.  Disparities in guideline-concordant treatment for node-positive, non-small cell lung cancer following surgery.

Authors:  Norma E Farrow; Selena J An; Paul J Speicher; David H Harpole; Thomas A D'Amico; Jacob A Klapper; Matthew G Hartwig; Betty C Tong
Journal:  J Thorac Cardiovasc Surg       Date:  2019-11-13       Impact factor: 5.209

3.  Effects of Delayed Surgical Resection on Short-Term and Long-Term Outcomes in Clinical Stage I Non-Small Cell Lung Cancer.

Authors:  Pamela Samson; Aalok Patel; Tasha Garrett; Traves Crabtree; Daniel Kreisel; A Sasha Krupnick; G Alexander Patterson; Stephen Broderick; Bryan F Meyers; Varun Puri
Journal:  Ann Thorac Surg       Date:  2015-04-16       Impact factor: 4.330

4.  Timing, Sites, and Correlates of Lung Cancer Recurrence.

Authors:  Chelsea M Karacz; Jingsheng Yan; Hong Zhu; David E Gerber
Journal:  Clin Lung Cancer       Date:  2019-12-20       Impact factor: 4.785

5.  Influence of medical comorbidities on the presentation and outcomes of stage I-III non-small-cell lung cancer.

Authors:  Daniel H Ahn; Nishi Mehta; Jeffrey T Yorio; Yang Xie; Jingsheng Yan; David E Gerber
Journal:  Clin Lung Cancer       Date:  2013-07-22       Impact factor: 4.785

6.  Elucidating patient-perceived role in "decision-making" among African Americans receiving lung cancer care through a county safety-net system.

Authors:  Simon Craddock Lee; Emily G Marks; Joanne M Sanders; Deborah J Wiebe
Journal:  J Cancer Surviv       Date:  2015-06-16       Impact factor: 4.442

7.  Patient navigation for lung cancer screening in an urban safety-net system: Protocol for a pragmatic randomized clinical trial.

Authors:  David E Gerber; Heidi A Hamann; Noel O Santini; Suhny Abbara; Hsienchang Chiu; Molly McGuire; Lisa Quirk; Hong Zhu; Simon J Craddock Lee
Journal:  Contemp Clin Trials       Date:  2017-07-05       Impact factor: 2.226

8.  Impact of renal function on treatment options and outcomes in advanced non-small cell lung cancer.

Authors:  Bercin Kutluk Cenik; Han Sun; David E Gerber
Journal:  Lung Cancer       Date:  2013-03-15       Impact factor: 5.705

9.  Multidisciplinary Treatment for Stage IIIA Non-Small Cell Lung Cancer: Does Institution Type Matter?

Authors:  Pamela Samson; Aalok Patel; Traves D Crabtree; Daniel Morgensztern; Cliff G Robinson; Graham A Colditz; Saiama Waqar; Daniel Kreisel; A Sasha Krupnick; G Alexander Patterson; Stephen Broderick; Bryan F Meyers; Varun Puri
Journal:  Ann Thorac Surg       Date:  2015-07-28       Impact factor: 4.330

10.  Non-small cell lung cancer treatment receipt and survival among African-Americans and whites in a rural area.

Authors:  Xinwei Hua; Kevin C Ward; Theresa W Gillespie; Joseph Lipscomb; Michael Goodman
Journal:  J Community Health       Date:  2014-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.